GlassScriptPhysician profile
Michael Lee Villano
NPI 1790752491
$10,766.12
in general payments reported to CMS, 2019-2025
33 companies · $1,861 in 2025
The $1,861 reported for 2025 was more than what 82% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,058 · 2020: $1,161 · 2021: $1,396 · 2022: $2,839 · 2023: $1,202 · 2024: $1,250 · 2025: $1,861.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,281 · Education: $31.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,281.15 |
| Education | $31.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,704.64 | 2021-2025 | Aurora Ev-Icd Mri Surescan |
| Astrazeneca Pharmaceuticals LP | $1,397.76 | 2019-2025 | Farxiga, Wainua, Brilinta |
| Janssen Pharmaceuticals, INC | $1,030.04 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $701.79 | 2021-2025 | Verquvo, Winrevair, Capvaxive |
| Novartis Pharmaceuticals Corporation | $676.65 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $668.43 | 2019-2023 | Opsumit |
| Amgen INC. | $628.40 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $457.99 | 2019-2025 | Camzyos, Eliquis |
| Novo Nordisk INC | $432.90 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $359.71 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $299.90 | 2020-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $297.11 | 2019-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $258.03 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $229.18 | 2019-2023 | |
| Amarin Pharma, INC. | $224.45 | 2019-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $198.63 | 2019-2020 | |
| Abiomed | $193.82 | 2022-2023 | Impella |
| Abbott Laboratories | $180.80 | 2021-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Mitraclip |
| Esperion Therapeutics, INC. | $174.24 | 2020-2025 | Nexletol |
| Boston Scientific Corporation | $162.04 | 2019-2023 | Ekosonic |
| Philips North America LLC | $146.96 | 2022-2025 | (Ck4) Mcot, Extended Holter, Ecc Solutions |
| Bayer Healthcare Pharmaceuticals INC. | $51.98 | 2022-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $43.86 | 2024 | Arcalyst |
| Irhythm Technologies, INC. | $41.87 | 2019-2022 | |
| Ethicon US, LLC | $38.51 | 2024 | Stratafix |
| Glaxosmithkline, LLC. | $31.78 | 2025 | Shingrix |
| Edwards Lifesciences Corporation | $26.93 | 2019 | |
| Cordis US Corp. | $22.46 | 2025 | Precise Pro Rx |
| Chiesi USA, INC. | $17.96 | 2019 | |
| Stryker Corporation | $17.81 | 2025 | Triever20 |
| Lilly USA, LLC | $17.23 | 2025 | Mounjaro, Zepbound |
| Baxter Healthcare | $16.84 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Dexcom, INC. | $15.42 | 2023 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Villano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.